Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00734877 · ClinicalTrials.gov registry record · Phase 3
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma
A Phase 3 study of Multiple Myeloma, sponsored by University of Arkansas.
- Active
- Registry status
- Phase 3
- Development phase
- 382
- Enrollment target
- 1
- Study location
NCT00734877: Active Phase 3 study of Multiple Myeloma, sponsored by University of Arkansas.
NCT00734877 is a Phase 3 study of Multiple Myeloma that is active but no longer recruiting, run by University of Arkansas. The registered enrollment target is 382 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00734877, a Phase 3 study of Multiple Myeloma, is active but no longer recruiting, sponsored by University of Arkansas.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 382 participants
- Enrollment target
- 1
- Study location
Study Summary
Toward improving the therapeutic index of standard TT3 (S-TT3), the investigators will employ a randomized Phase III trial design to determine whether S-TT3 treatment-related toxicities can be reduced by 50% in TT3-Lite (L-TT3). Note: Randomization has been discontinued and accrual is closed to the L-TT3 arm. This trial is currently enrolling as a single-arm trial for patients to receive S-TT3.
Conditions Studied
Interventions
- DRUG M-VTD-PACE
- DRUG TT3-LITE Regimen (L-TT3)
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 382 participants |
| Start Date | 2008-07 |
| Est. Completion | 2027-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00734877
The ClinicalTrials.gov registry entry for NCT00734877 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 382 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (30% lower). The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which M-VTD-PACE is the first listed.
NCT00734877 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT00734877 about?
NCT00734877 is a clinical study titled "UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma". Toward improving the therapeutic index of standard TT3 (S-TT3), the investigators will employ a randomized Phase III trial design to determine whether S-TT3 treatment-related toxicities can be reduced by 50% in TT3-Lite (L-TT3). Note: Randomization has been discontinued and accrual is closed to the...
What is the current status of trial NCT00734877?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 382 participants. The study started on 2008-07. Estimated completion is 2027-09.
What conditions does trial NCT00734877 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00734877?
The interventions under investigation include: M-VTD-PACE (DRUG), TT3-LITE Regimen (L-TT3) (DRUG).
Who is sponsoring clinical trial NCT00734877?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00734877 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.